Girard Partners’s GSK GSK Stock Holding History

Girard Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,336	Closed	-$67K	–	457
2018 Q3	$67K	Buy	+1,336	New	+$67.9K	0.01%	405

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Girard Partners's GSK Position: Q4 2018 in Review

Girard Partners sold out of GSK (GSK) in Q4 2018, closing a stake of 1,336 shares — an estimated $67K sold.

Girard Partners first reported a position in GSK in Q3 2018 and held it in 1 quarter. The position peaked at $67K in Q3 2018. 799 funds tracked by Wall St. Rank hold GSK as of Q4 2018.

Girard Partners reported no remaining GSK position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 1,336 GSK shares in Q4 2018, an estimated $67K.
Girard Partners first reported a position in GSK in Q3 2018 and held it in 1 quarter.
Girard Partners's GSK position peaked at $67K in Q3 2018.
799 funds tracked by Wall St. Rank held GSK as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.